Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
Background. Overactive bladder (OAB) is characterized by urgency and frequency with (OAB wet) or without (OAB dry) urge urinary incontinence (UUI). In the phase 3 EMPOWUR trial, vibegron—a selective β3-adrenergic receptor agonist for the treatment of OAB—significantly improved daily number of urgenc...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | International Journal of Clinical Practice |
| Online Access: | http://dx.doi.org/10.1155/2022/6475014 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|